DOCSLIB.ORG

Healthcare in China Entering Uncharted Waters

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Healthcare in China Entering Uncharted Waters Healthcare in China Entering uncharted waters Healthcare Healthcare in China Entering uncharted waters September 2012 2 Preface The Chinese government is committed to their capabilities, and aspire to strategic improvement of the healthcare system and alliances and international expansion. development of the healthcare industry Insurance companies and healthcare as clear strategic priorities. Reforms providers are also beginning to benefit from the announced in 2009 set the ambitious goal government’s resolute steps towards opening of providing universal access to effective, up the market. By allowing private companies safe, and low-cost healthcare by 2020. to play a larger role, the government will enable The 12th Five-Year Plan, issued in March a significant inflow of new entrants who are 2011, encourages innovation throughout eager to tap into the primary opportunities in the biomedical industry, broadly defined as health insurance, private hospitals and clinics, covering pharmaceuticals, vaccines, medical and in the services such as healthcare IT that products and traditional Chinese medicine. underpin them. Its designation as a ‘strategic industry’ leads to government support through significant Many of the ingredients are in place for flows of public funds and favorable policy- the continuation of strong growth of the changes, many of which have yet to be healthcare sector. We believe however that conceived and articulated. These various the path ahead will be more challenging, policies will offer extensive opportunities for reflecting the ambition and the scale participants in every sector of the industry. of the transformation under way. In the words of vice-premier Li Keqiang, China’s Spending on healthcare for the China’s healthcare system has entered ‘uncharted vast population is on a fast track to reach waters’. While healthcare reform has had $1 trillion by 2020. Multinational companies notable successes, such as the expansion recognize the commercial opportunities of insurance coverage to 95% of the and have made China a strategic priority: for population, there are some real issues many pharmaceutical and medical products to resolve. Serious questions about the companies, the country is now a ‘top-three’ funding of healthcare and the role of public market in terms of revenue contribution, hospitals have yet to be settled; there are and even number one for absolute uncertainties relating to the recognition and revenue growth. These companies are protection of intellectual property; tensions establishing manufacturing sites and R&D may arise in simultaneously developing a centers, along with field-forces comprising low-cost healthcare system and promoting sales representatives numbering in the significant investment in innovation. In the thousands. Decision centers with regional commercial sector, the ‘uncharted waters’ or even global mandates are starting to be include increasing pricing pressures, relocated to China. For domestic players, intensifying competition, the fragmented the government is keen to see national and uneven market-access environment, champions emerge, and is encouraging and the fundamental challenges to business Chinese companies to consolidate, upgrade models that these upheavals demand. Healthcare in China Entering uncharted waters 3 Nonetheless, China’s healthcare sector pharmaceutical and medical products remains a remarkably positive story. In markets; the continuing transformation this report—Healthcare in China: Entering of the healthcare service system; and the uncharted waters—McKinsey & Company’s challenges facing industry players that are Greater China Healthcare practice offers a building up their capabilities. diversity of perspectives on this substantial, We hope you will find this report an interesting complex and important domain. This window through which to survey one of the compendium of articles is organized into great healthcare stories of our time. three main themes: opportunities in the Franck Le Deu Rajesh Parekh Claudia Süssmuth Dyckerhoff Partner, Partner, Partner, McKinsey & Company, McKinsey & Company, McKinsey & Company, Shanghai Shanghai Shanghai 4 Contents Preface .......................................................................................................... 2 McKinsey & Company Greater China Healthcare Practice Leadership ............ 6 Overview Healthcare in China: ‘Entering uncharted waters’ ..........................................11 Franck Le Deu, Rajesh Parekh, Fangning Zhang, and Gaobo Zhou Opportunities in the pharmaceutical and medical products markets Big Pharma in China: Time to rethink the commercial model ......................... 29 Bing Chen, Franck Le Deu, and Jin Wang A six-point plan for launching new pharmaceutical products in China ........... 39 Bing Chen, Franck Le Deu, and Jin Wang Modern perspectives on traditional Chinese medicine ................................. 49 Bing Chen and Jin Wang Pills, potions, and potential: The consumer healthcare opportunity in China ............................................ 59 Rajesh Parekh, Felix Poh, and Ari Silverman Taking the best shot at China’s vaccines market ........................................... 69 Yinuo Li, Li Ma, and Rajesh Parekh Tailwinds but with turbulence: The outlook for China’s medical products industry ........................................ 81 Lifeng Chen, Yinuo Li, Rajesh Parekh, and Jin Wang From imitation to innovation in medical products: The ascent of China’s local players ............................................................... 91 Lifeng Chen, Yinuo Li, Rajesh Parekh, and Fangning Zhang Healthcare in China Entering uncharted waters 5 Transformation of the healthcare service system Top-down architectural framework for China’s public hospital reform: An interview with Mr. Rao Keqin, a thought leader on the reform .................. 103 Yinuo Li and Li Ma Private hospitals in China: Connecting the dots ...........................................113 Alexander Ng, Claudia Süssmuth Dyckerhoff, and Florian Then Private health insurance in China: Finding the winning formula .....................125 Alexander Ng, Claudia Süssmuth Dyckerhoff, and Florian Then Seeing healthcare reform through physicians’ eyes: Highlights from McKinsey’s 2012 physician survey ..................................... 133 Yinuo Li, Li Ma, and Claudia Süssmuth Dyckerhoff Building up capabilities Pharmaceutical R&D in China: Placing the winning bets on innovation ......... 145 Laura Nelson Carney, Jeremy Teo, and Fangning Zhang Debunking the myths about R&D talent in China ......................................... 155 Laura Nelson Carney, Keith Lostaglio, Jeremy Teo, and Fangning Zhang Regionalization: Lessons from pharmacos that have ‘tasted the crab’ ......... 165 Tian-Cho Chu, Ari Silverman, and Gaobo Zhou China’s digital healing .................................................................................175 Cindy Chiu, Chris Ip, Ari Silverman, and Florian Then About us .................................................................................................... 182 6 McKinsey & Company Greater China Healthcare Practice Leadership Rajesh Parekh Jin Wang Partner – Shanghai Partner – Shanghai Claudia Süssmuth Ari Silverman Dyckerhoff Partner – Shanghai Partner – Shanghai Franck Le Deu Yinuo Li Partner – Shanghai Partner – Beijing Healthcare in China Entering uncharted waters 7 Bing Chen Jeremy Teo Associate Partner – Associate Partner – Shanghai Shanghai Laura Nelson Carney Gaobo Zhou Associate Partner – Associate Partner – Hong Kong Hong Kong Alexander Ng Contributors to the articles in this volume also Associate Partner – include: Lifeng Chen, Cindy Chiu, Tian-Cho Chu, Hong Kong Chris Ip, Keith Lostaglio, Li Ma, Felix Poh, Florian Then and Fangning Zhang 8 Healthcare in China Entering uncharted waters 9 Overview 10 Healthcare in China: ‘Entering uncharted waters’ Healthcare in China Entering uncharted waters 11 Healthcare in China: ‘Entering uncharted waters’ Franck Le Deu, Rajesh Parekh, Fangning Zhang, and Gaobo Zhou China’s healthcare sector continues to develop at an astonishing rate. The nation’s healthcare spending is projected to grow from $357 billion in 2011 to $1 trillion in 2020. Across key categories, from pharmaceuticals to medical products and consumer health, China remains one of the world’s most attractive markets, and is by far the fastest-growing of all the large emerging markets. It is not surprising that multinationals are flocking to take advantage of the opportunities, but long- term success for all participants is by no means assured. Although we remain optimistic about the overall outlook for the healthcare market in China, we believe it will become more difficult for multinationals to compete. We expect a clearer separation between winners and laggards, and late entrants could face a struggle to achieve real traction. At a high level of analysis, three themes will shape China’s healthcare market in the coming years: the continuation of economic and demographic trends, further healthcare reform, and the policies articulated in the government’s 12th Five-Year Plan (FYP). Some of these forces will have positive implications for multinational companies, for example, improvements in infrastructure, the broadening of insurance coverage, and significant support for innovation. Some of them will have negative implications, for example, pressures on pricing, and the rise of local champions. In some situations the forces come into direct opposition,
Load more

Recommended publications
  • Potential Opportunities from One of the Fastest Growing Major Global Healthcare Markets1
    KURE 3/31/2018 China Healthcare: Potential Opportunities From One Of The Fastest Growing Major Global Healthcare Markets1 An Overview of the KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) 1. Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2015. Retrieved 3/31/2018 [email protected] 1 Introduction to KraneShares About KraneShares Krane Funds Advisors, LLC is the investment manager for KraneShares ETFs. Our suite of China focused ETFs provides investors with solutions to capture China’s importance as an essential element of a well-designed investment portfolio. We strive to provide innovative, first to market strategies that have been developed based on our strong partnerships and our deep knowledge of investing. We help investors stay up to date on global market trends and aim to provide meaningful diversification. Krane Funds Advisors, LLC is majority owned by China International Capital Corporation (CICC). 2 Investment Strategy: KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The KURE securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.
    [Show full text]
  • Journal of Current Chinese Affairs
    China Data Supplement March 2008 J People’s Republic of China J Hong Kong SAR J Macau SAR J Taiwan ISSN 0943-7533 China aktuell Data Supplement – PRC, Hong Kong SAR, Macau SAR, Taiwan 1 Contents The Main National Leadership of the PRC ......................................................................... 2 LIU Jen-Kai The Main Provincial Leadership of the PRC ..................................................................... 31 LIU Jen-Kai Data on Changes in PRC Main Leadership ...................................................................... 38 LIU Jen-Kai PRC Agreements with Foreign Countries ......................................................................... 54 LIU Jen-Kai PRC Laws and Regulations .............................................................................................. 56 LIU Jen-Kai Hong Kong SAR ................................................................................................................ 58 LIU Jen-Kai Macau SAR ....................................................................................................................... 65 LIU Jen-Kai Taiwan .............................................................................................................................. 69 LIU Jen-Kai ISSN 0943-7533 All information given here is derived from generally accessible sources. Publisher/Distributor: GIGA Institute of Asian Studies Rothenbaumchaussee 32 20148 Hamburg Germany Phone: +49 (0 40) 42 88 74-0 Fax: +49 (040) 4107945 2 March 2008 The Main National Leadership of the
    [Show full text]
  • Inside This Issue
    1 December 23, 2014 – Issue 122 INSIDE THIS ISSUE China Green Food Expo to be Held in Nanchang China Green Food Expo to be The seventh China Green Food Expo is to be held in Nanchang, Held in Nanchang Jiangxi province. Companies from more than 30 provinces will attend the Expo with thousands of attendees to the event. Jan-Oct China Health Insurance The event is co-held by Ministry of Commerce and Jiangxi local Premium Exceeded CNY 130bn government. CFDA: Cosmeceuticals Should not The Expo tends to promote the economic rise of middle area of Promote Itself as Medicines the country and the opening-up of Jiangxi province. The event will include the food expo and a cooperation seminar joined by Shi Jiazhuang to Crack Down on state-run companies with local food providers and vendors. Illegal Health Food and Cosmetics The Expo mainly features low-carbon industry and green food. It will cover six indoor exhibiting rooms with food companies from Amorepacific Taps Surging more than 30 provinces. Overseas vendors from Australia, Demand for Midrange Beauty America, Russia and Thailand will also bring food to the local Products consumers who will attend the expo. （Source: Food Safety Daily) China Nepstar: A Bitter Pill For Investors Jan-Oct China Health Insurance Premium Exceeded CNY 130bn Herbal Berberine Boosts Brown Fat Activity Premium income of health insurance exceeded CNY 136.656 billion in the first 10 months of this year, growing 45.25% year on year, according to China Insurance Regulatory Commission. Premium income of life insurance companies grew 19.36% year on year.
    [Show full text]
  • Issue 1 2013
    ISSUE 1 · 2013 NPC《中国人大》对外版 CHAIRMAN ZHANG DEJIANG VOWS TO PROMOTE SOCIALIST DEMOCRACY, RULE OF LAW ISSUE 4 · 2012 1 Chairman of the NPC Standing Committee Zhang Dejiang (7th, L) has a group photo with vice-chairpersons Zhang Baowen, Arken Imirbaki, Zhang Ping, Shen Yueyue, Yan Junqi, Wang Shengjun, Li Jianguo, Chen Changzhi, Wang Chen, Ji Bingxuan, Qiangba Puncog, Wan Exiang, Chen Zhu (from left to right). Ma Zengke China’s new leadership takes 6 shape amid high expectations Contents Special Report Speech In–depth 6 18 24 China’s new leadership takes shape President Xi Jinping vows to bring China capable of sustaining economic amid high expectations benefits to people in realizing growth: Premier ‘Chinese dream’ 8 25 Chinese top legislature has younger 19 China rolls out plan to transform leaders Chairman Zhang Dejiang vows government functions to promote socialist democracy, 12 rule of law 27 China unveils new cabinet amid China’s anti-graft efforts to get function reform People institutional impetus 15 20 28 Report on the work of the Standing Chairman Zhang Dejiang: ‘Power China defense budget to grow 10.7 Committee of the National People’s should not be aloof from public percent in 2013 Congress (excerpt) supervision’ 20 Chairman Zhang Dejiang: ‘Power should not be aloof from public supervision’ Doubling income is easy, narrowing 30 regional gap is anything but 34 New age for China’s women deputies ISSUE 1 · 2013 29 37 Rural reform helps China ensure grain Style changes take center stage at security Beijing’s political season 30 Doubling
    [Show full text]
  • China Digest
    China Digest China by numbers Round-up of business news, current issues, • 13,548 meters - combined height of and M&A analysis skyscrapers built in China in 2014 • 3 – number of world’s 10 tallest buildings Q1 2015 built in Wuxi city in 2014 • 7% - share of global freshwater in China In the news … (vs. 20% of world population) • 7 - of China’s ten most polluted cities are Subsidies cut for non-electric vehicles [Auto] in Hebei province The Ministry of Finance reports it is to reduce subsidies for traditional vehicles in • 30,000 - number of TV drama episodes an effort to boost the country’s renewable energy vehicle market. A program to build made in China annually charging infrastructure will also be accelerated. Aside from helping reduce urban pollution levels, the subsidy cut could encourage take-up of electric and hybrid • 14 - number of countries bordering China vehicles and boost domestic manufacturers such as BYD. (Caixin) • 648 million - China's online population • 280 million - number of people in China Growth of China O&G consumption to slow in 2015 [Energy] without safe drinking water China’s oil & gas consumption is expected to see slower growth this year, with falling • $1,831 - President Xi Jinping’s monthly global crude prices providing an opportunity for more energy sector reforms, salary according to the Economic and Technology Research Institute of the country’s • $1.2billion - annual US drug exports to largest O&G producer, China National Petroleum Corp. Chinese oil demand will China grow 3% year-on-year to 534 million metric tons in 2015, compared to growth of • $119.6 billion - China's actual use of 3.3% (to 516 million tons) in 2014, it said.
    [Show full text]
  • 2018 Unaudited Semiannual Report
    BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) Contents Pages Management and Administration 1 Report of the Manager to the Unitholders 2 Statement of Financial Position (Unaudited) 3 Investment Portfolio (Unaudited) 4 – 5 Statement of Movements in Investment Portfolio (Unaudited) 6 – 9 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) MANAGEMENT AND ADMINISTRATION Manager Directors of the Manager BOCOM International Asset Management Limited TAN Yueheng 9/F, Man Yee Building LI Ying 68 Des Voeux Road Central CHENG Chuange Central Hong Kong Trustee and Registrar Bank of Communications Trustee Limited 1/F, Far East Consortium Building 121 Des Voeux Road Central Central Hong Kong PRC Custodian HSBC Bank (China) Company Limited 33/F, HSBC Building, Shanghai ifc 8 Century Avenue, Pudong Shanghai Legal Counsel to the Manager Deacons 5/F, Alexandra House 18 Chater Road Central Hong Kong Auditor PricewaterhouseCoopers 21/F, Edinburgh Tower 15 Queen’s Road Central Hong Kong - 1 - SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) REPORT OF THE MANAGER TO THE UNITHOLDERS The A-share market under-performance in 1H2018 can be attributed to two main factors: 1) the United States entered an interest rate hike cycle, which caused wide concern about the emerging market’s debt problems.
    [Show full text]
  • Interview with Beijing Tong Ren Tang/Science Arts
    [ Interview ] Mr Tan Lee Huak, owner of Science Arts Co Pte Ltd. Interview with Beijing Tong Ren Tang/Science Arts eijing Tongrentang, was founded in Kangxi 8. It is a famous time-honored brand in the Traditional Chinese Medicine industry. Science Arts collaborated Bwith Beijing Tong Ren Tang in 2004 and brought this well established brand to Singapore. Beijing Tong Ren Tang has a long Beijing Tong Ren Tang has outlets in many countries in the Asia history, being founded in the Kangxi Pacific. Its headquaters is in Beijing, China. The company has period, in 1669. Can you share with collaborated with more than 20 distributors worldwide. They us how the collaboration between have stores in the UK, Australia, Canada and countries in the Asia Pacific. Beijing Tong Ren Tang and Science It has also partnered with various distributors and companies in different Arts came about? countries. In Malaysia, they have partnered with “Hai Ou” to distibute their products. Here in Singapore, Science Arts is its sole distributor. Science Arts and Beijing Tong Ren Tang went into a collaboration in 2004. 1146 ■ Volume 11 > Number 16 > 2007 www.asiabiotech.com [ Interview ] What is Science Arts history and Science Arts have been around for 30 odd years. It was set up how did it come about? by a group of young passionate fresh graduates from The Chinese High School in the 1960s. The collaboration with Beijing Tong Ren Tang is 51% stakes held by Science Arts and 49% belongs to Beijing Tong Ren Tang. What are some of the measures that The side effects of most of our products are minimal.
    [Show full text]
  • Feb 2018.Cdr
    VOL. XXX No. 2 February 2018 Rs. 20.00 The Chinese Embassy in India held a symposium with The Chinese Embassy in India, ICCR and China some eminent people of India. Federation of Literary and Art Circles co-hosted Guangzhou Ballet Performance. Ambassador Luo Zhaohui met with a delegation from the Ambassador Luo Zhaohui met with students from Ministry of Foreign Affairs of the PRC. Experimental School of Capital Normal University. Minister and DCM Mr. Li Bijian participated in an activity Diplomats of Chinese Embassy attended the in Jindal Global University. International Food Festival in JNU. Celebrating Spring Festival 1. Entering the Year of the Dog 4 2. Old, New Customs to Celebrate China’s Spring Festival 7 3. China Focus: Traditional Spring Festival Holiday Picks up New Ways 10 of Spending 4. China Focus: Spring Festival Travel Mirrors China’s Changes Over 40 Years 13 5. China Holds Spring Festival Gala Tour for Overseas Chinese 15 6. 6.5 Mln. Chinese to Travel Overseas During Spring Festival Holiday 16 7. Time for Celebrating Chinese New Year 17 8. Indispensable Dishes that Served During China’s Spring Festival 19 9. Spring Festival: Time to Show Charm of Diversification with 56 Ethnic Groups 21 External Affairs 1. Xi Jinping Meets with UK Prime Minister Theresa May 23 2. Xi Jinping Meets with King Willem-Alexander of the Netherlands 25 3. Working Together to Build a Better World 26 4. Li Keqiang and Prime Minister Theresa May of the UK Hold Annual 31 China-UK Prime Ministers’ Meeting 5. Li Keqiang Meets with Foreign Minister Taro Kono of Japan 33 6.
    [Show full text]
  • Healthcare Sector
    19 August 2013 Sector Weekly Healthcare Sector Healthcare Sector Weekly Dose Valuation summary Company Ticker CCY Px Mkt ––––– P/E ––––– EPS CAGR –––– PEG –––– –––– P/B –––– –––– ROE –––– This weekly product is designed to provide investors with key sector cap '13E '14E '15E ('12E -'15E) '13E '14E '15E '13E '14E '15E '13E '14E '15E updates and our attempt to identify (USD) (x) (x) (x) (%) (x) (x) (x) (x) (x) (x) (%) (%) (%) stock implications and insights. Shandong Weigao Group Medical 1066 -HK HKD 8.09 1,965 24.2 19.9 16.4 22 1.1 0.9 0.7 2.9 2.6 2.3 12.1 13.2 14.3 Polymer Co. Ltd. Class H Topics this week: Bribery investigation, China Shineway Pharmaceutical 2877 -HK HKD 12.72 1,356 11.8 10.5 9.4 12 1.0 0.9 0.8 1.8 1.7 1.5 16.0 16.3 16.5 H7N9 resurfacing, NDRC might adjust Group Limited originator drug px, June ’13 hospital United Laboratories International 3933 -HK HKD 2.92 613 18.3 13.0 10.6 26 0.7 0.5 0.4 0.7 0.7 0.7 3.8 5.2 6.1 patient traffic data Holdings Ltd. Sinovac Biotech Ltd. SVA -US USD 4.61 254 -26.3 -43.9 46.1 2.3 2.6 2.7 -8.7 -6.0 5.9 Companies mentioned: Weigao (1066-HK), Shineway (2877.HK) and The China Nepstar Chain Drugstore NPD -US USD 1.58 156 21.3 Ltd. Sponsored ADR United Labs (3933.HK), Sinovac (SVA.O) and Nepstar (NPD.N) Source: Factset/Bloomberg SAIC anti-bribery investigation to begin: The State Administration for Industry and Commerce (SAIC) has initiated a round of bribery investigation that is expected to last 3 months until November ‘13.
    [Show full text]
  • China Pharmaceutical Newsletter
    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
    [Show full text]
  • Pharmaceuticals in China
    INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS CLICK TO VIEW Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom Research, Related Studies, Corporate Use License 8 Pharmaceuticals in China China Industry Study with Forecasts to 2010 & 2015 Study #2024 | February 2006 | $4800 | 240 pages The Freedonia Group 767 Beta Drive www.freedoniagroup.com Cleveland, OH • 44143-2326 • USA Toll Free US Tel: 800.927.5900 or +1 440.684.9600 Fax: +1 440.646.0484 E-mail: [email protected] Study #2024 February 2006 Pharmaceuticals in China $4800 240 Pages China Industry Study with Forecasts to 2010 & 2015 Table of Contents INTRODUCTION Shipments .......................................62 Corticosteroids ............................ 115 Types of Medicines ............................63 Estrogens & Combinations ............. 115 Astragalus ....................................64 Other Hormones ........................... 116 EXECUTIVE SUMMARY Atractylodes ..................................66 Shipments ..................................... 117 Bupleurum ....................................67 Biologicals & Vaccines ........................ 119 MARKET ENVIRONMENT China Root ....................................67 Demand ......................................... 120 General ..............................................4 Cinnamon .....................................68 Vaccines ..................................... 120
    [Show full text]
  • Completing the Deal
    termsheet April 2018 Issue 24 Completing the Deal industry insight An Interview with Dr Fintan Walton, Are Traditional Chinese Medicines Founder and Chief Executive of PharmaVentures and Plant Extract Treatments the Basis of New Licensing and M&A As Fintan Walton, the Founder and CEO of PharmaVentures, puts it himself, Growth? he was “fortunate enough to be able to enter the world of pharmaceuticals Eric Liu when the explosion of biotechnology Business Analyst, PharmaVentures Limited took off in the 1970’s and 1980s”. He Traditional Chinese Medicines (TCMs) are gaining was educated at Trinity College, Dublin interest worldwide. However despite being as a geneticist and entered the world practised by significant numbers of people in more of biotechnology in the UK by joining Celltech, the first biotech than 140 countries, the absence of robust evidence of efficacy in Europe, in the early 1980s. What Fintan finds fascinating about and safety in conventional clinical trials remains a key challenge that period was that the technology being developed enabled in mainstream commercial adoption, through licensing and M&A scientists to really understand the basis of disease and hence, transactions. Against this backdrop 2017 was a milestone year. The come up with truly break-through medicines as more and more University of Oxford opened its first Chinese Medicine Research biotech companies emerged worldwide. “Their research led to Centre on 6th December, which is one of the first research centres inventions and so the opportunity to license patents and do deals in the West that solely focuses on the study of herbal extracts became a real driver in the biotech industry”.
    [Show full text]